Skip to main content

Table 1 The results of allogeneic CAR-T cell infusion after allogeneic transplantation in B cell malignancies

From: Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Author

No. of patients

Disease

Activation motif of CAR

Dose of infused CAR-T

No. of GVHD

Toxicities

Outcomes

Kochenderfer et al.

10

CLL, DLBCL, and MCL

28

Between 0.4 × 106/kg and 7.8 × 106/kg

No

Fatigue, fever, and hypotension

1 CR, 1 PR, and 6 with stable disease

Cruz et al.

8

CLL and ALL

28

Escalation schedule of 1.5 × 107/m2, 4.5 × 107/m2, and 1.2 × 108/m2

No

No

2 CR(1 remained in CR for 8 months and the other 1 for 8 weeks)

Brudno et al.

20

CLL, DLBCL, MCL, and ALL

28

From 106/kg to 107/kg

2 (mild chronic GVHD)

Fever, tachycardia, and hypotension

8 of 20 patients obtained remission (6 CR and 2 PR)

Zuo et al.

1

ALL

28, 137, and 27

First dose 106/kg and three maintenance (from 0.83 × 106 to 1.65 × 106/kg)

No

Mild or moderate CRS

DFS for 10 months

Grupp et al.

1

ALL

28

1.4 × 106/kg

No

Fever

MRD-negative CR at approximately 1 month and relapse after 2 months

  1. CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, ALL acute lymphoblastic leukemia, CAR chimeric antigen receptor, CAR-T chimeric antigen receptors redirected T cells, GVHD graft-versus-host disease, CRS cytokine release syndrome, CR complete remission, PR partial remission, DFS disease-free survival, MRD minimal residual disease